Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

Regorafenib (off Label)

Regorafenib in ACC

Memorial Sloan Kettering (investigator) · Phase 2 · Completed · Enrollment 38

NCT02098538

ArmReported safety
Regorafenibpatients with serious adverse events: 14 patients (of 38), results posted

A count stays a count. This page does not turn a count into a percent.